Drug intelligence / Profile preview

Winzac

Development stage: Unknown
Lead developer: Nilegenix
Modality: Small Molecules
Administration: Oral

Overview

Winzac is a nutritional supplement developed and marketed by Nilegenix, a generic pharmaceutical company based in Sangli, Maharashtra, India. It is specifically formulated to support bone health and address calcium deficiency. As a nutritional supplement, it provides essential minerals required for bone mineralization and structural integrity. It is commercially available as an approved product in the Indian market, intended for individuals requiring calcium supplementation to maintain skeletal health or treat deficiency-related conditions.

Brand names: Winzac

Beyond the preview

Go deeper on Winzac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Winzac.

Explore the full profile